Clinical Stage Drugs
For Rare and Common Diseases
with Unmet Need
Acctena's strategy is to bring selected drugs directly into phase 2 studies for new clinical use and expanded intellectual property
By evaluating study data and mechanism of action, experienced drug developers can identify diseases where these “abandoned” drugs can become beneficial medicines .
Acctena is Built on
Two Platforms with Near Term PoC
MESSAGE FROM OUR BOARD
"Acctena offers reduced risk for investors due to its diversified development portfolio consisting of drugs that have already been studied in man.
Revive your clinical drug
Unlock the full potential of your abandonned clinical drug.
Apply for a chance to become part of Acctena's program.